Open access · CC-BY
via OpenAlex
Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
Hongcai Li, Jingjing Liang, Mengzhen Han, Zhenpeng Gao
Journal of Advanced Research · 2024 · ▲ 71 citations
Abstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease with an increasing incidence worldwide. Single drug therapy may have toxic side effects and disrupt gut microbiota balance. Polyphenols are widely used in disease intervention due to their distinctive nutritional properties and medicinal value, which a potential gut microbiota modulator. However, there is a lack of comprehensive review to explore the efficacy and mechanism of combined therapy with drugs and polyphenols for NAFLD. AIM OF REVIEW: Based on this, this review firstly discusses the link between NAFLD and gut microbiota, and outlines the effects of polyphenols and drugs on gut microbiota. Secondly, it examined recent advances in the treatment and intervention of NAFLD with drugs and polyphenols and the therapeutic effect of the combination of the two. Finally, we highlight the underlying mechanisms of polyphenol combined drug therapy in NAFLD. This is mainly in terms of signaling pathways (NF-κB, AMPK, Nrf2, JAK/STAT, PPAR, SREBP-1c, PI3K/Akt and TLR) and gut microbiota. Furthermore, some emerging mechanisms such as microRNA potential biomarker therapies may provide therapeutic avenues for NAFLD. KEY SCIENTIFIC CONCEPTS OF REVIEW: Drawing inspiration from combination drug strategies, the use of active substances in combination with drugs for NAFLD intervention holds transformative and prospective potential, both improve NAFLD and restore gut microbiota balance while reducing the required drug dosage. This review systematically discusses the bidirectional interactions between gut microbiota and NAFLD, and summarizes the potential mechanisms of polyphenol synergistic drugs in the treatment of NAFLD by modulating signaling pathways and gut microbiota. Future researches should develop multi-omics technology to identify patients who benefit from polyphenols combination drugs and devising individualized treatment plans to enhance its therapeutic effect.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.jare.2024.03.004
- Canonical
- link ↗
- Fetched
- 2026-06-29 MST
Cite this
APA
Li, H., Liang, J., Han, M., & Gao, Z. (2024). Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review. <em>Journal of Advanced Research</em>. https://doi.org/10.1016/j.jare.2024.03.004
Vancouver
Li H, Liang J, Han M, Gao Z. Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review. Journal of Advanced Research. 2024. doi:10.1016/j.jare.2024.03.004.
BibTeX
@article{hongcai2024Polyph,
title = {Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review},
author = {Hongcai Li and Jingjing Liang and Mengzhen Han and Zhenpeng Gao},
journal = {Journal of Advanced Research},
year = {2024},
doi = {10.1016/j.jare.2024.03.004},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Tissue Engineering and Regenerative Medicine 2025
Open access · CC-BY
Combination Therapy of Losartan and Fisetin Reduces Senescence and Enhances Osteogenesis in Human Bone Marrow–Derived Mesenchymal Stem Cells
Molecular and Cellular Endocrinology 2016
Preprint · OA
Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging
Frontiers in Endocrinology 2020
Open access · CC-BY
Metformin and Its Benefits for Various Diseases
International Journal of Molecular Sciences 2019
Open access · CC-BY
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature
BioMed Research International 2017
Open access · CC-BY
Cellular Mechanisms of Liver Regeneration and Cell-Based Therapies of Liver Diseases
Pharmaceuticals 2023
Open access · CC-BY